You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Vandetanib, NSCLC, Maintenance, Phase II

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stage IV NSCLC Trial in Dallas (Stereotactic Body Radiation Therapy, Maintenance chemo)

Completed
  • Stage IV Non-Small Cell Lung Cancer
  • Stereotactic Body Radiation Therapy
  • Maintenance chemotherapy
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 30, 2022

Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

Not yet recruiting
  • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
  • New York, New York
    NYU Langone Health
Apr 4, 2023

NSCLC Trial in Guangzhou (Neratinib tablets)

Not yet recruiting
  • NSCLC
  • Neratinib tablets
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 1, 2023

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial (Osimertinib, Aspirin)

Not yet recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • (no location specified)
Aug 27, 2023

NSCLC Trial (Atezolizumab, Tiragolumab)

Not yet recruiting
  • NSCLC
  • (no location specified)
Apr 5, 2023

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

NSCLC Trial in Shanghai (IN10018, Furmonertinib)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 8, 2023

Relapsed Ovarian Cancer Trial (Fluzoparib, Apatinib)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Oct 7, 2023

Colorectal Carcinoma Trial (Fruquintinib?Capecitabine Tablets)

Not yet recruiting
  • Colorectal Carcinoma
  • Fruquintinib、Capecitabine Tablets
  • (no location specified)
Oct 30, 2023

NSCLC Trial in Shanghai (SBRT+LDRT, Toripalimab, Chemotherapy drug)

Recruiting
  • NSCLC
  • SBRT+LDRT
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Apr 2, 2023

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

NSCLC Trial (Atezolizumab, Tiragolumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Apr 11, 2023

Oligometastatic Disease, Metastatic Non Small Cell Lung Cancer Trial in Mumbai (Local consolidative radiation therapy, Standard

Recruiting
  • Oligometastatic Disease
  • Metastatic Non Small Cell Lung Cancer
  • Local consolidative radiation therapy
  • Standard maintenance therapy as decided by the treating medical oncologist
  • Mumbai, Maharashtra, India
    Tata Memorial Hospital, Parel
Mar 11, 2022

Squamous NSCLC, Non-Squamous NSCLC Trial (Durvalumab, Tremelimumab)

Withdrawn
  • Squamous Non-small Cell Lung Cancer
  • Non-Squamous Non-small Cell Lung Cancer
  • (no location specified)
Dec 17, 2021

Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult, KRAS G12C Trial (JDQ443)

Not yet recruiting
  • Non Small Cell Lung Cancer Metastatic
  • +2 more
  • (no location specified)
Aug 11, 2023

Cancer, Non Small Cell Lung Cancer Trial in United Kingdom (Vandetanib, Selumetinib)

Completed
Has Results
  • Cancer
  • Non Small Cell Lung Cancer
  • Vandetanib, Selumetinib
  • Headington, Oxford, United Kingdom
  • +3 more
Sep 9, 2021

Small-cell Lung Cancer Trial in Guangzhou (Serplulimab)

Recruiting
  • Small-cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial Perople's Hospital
Jul 20, 2023

Metastatic Cancer, Urothelial Carcinoma Trial (avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin)

Not yet recruiting
  • Metastatic Cancer
  • Urothelial Carcinoma
  • avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
  • (no location specified)
Dec 19, 2022

NSCLC, NSCLC, PD-1 Trial in Beijing (F520, Pemetrexed, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Feb 22, 2023

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

Advance NSCLC Trial (GFH925, Cetuximab)

Not yet recruiting
  • Advance Non-small Cell Lung Cancer
  • (no location specified)
Mar 7, 2023

NSCLC Trial in Singapore (Afatinib 40 MG)

Not yet recruiting
  • NSCLC
  • Afatinib 40 MG
  • Singapore, Singapore
    National University Hospital
Sep 25, 2023

Furmonertinib, EGFR-mutation, NSCLC Trial in Beijing (Furmonertinib)

Recruiting
  • Furmonertinib
  • +3 more
  • Beijing, China
    Ethics Committee
Jul 15, 2022

Non Small Cell Lung Cancer Trial (HLX208+HLX10)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • HLX208+HLX10
  • (no location specified)
Nov 30, 2022

Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))

Not yet recruiting
  • Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
  • intensity-modulated radiotherapy (IMRT)
  • (no location specified)
Jun 4, 2023